Madrigal Pharmaceuticals (MDGL) Enterprise Value (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Enterprise Value data on file, last reported at -$232.2 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 72.45% year-over-year to -$232.2 million in Q1 2026; TTM through Mar 2026 was -$232.2 million, a 72.45% increase from a year earlier, with the FY2025 full-year figure at -$983.6 million, down 836.55% from the prior year.
• Enterprise Value for Q1 2026 stood at -$232.2 million, up from -$983.6 million in the prior quarter.
• Over the last five years, Enterprise Value for MDGL reached as high as -$105.0 million in Q4 2024 and fell as low as -$1.1 billion in Q3 2025.
• Historically, Enterprise Value has averaged -$566.1 million across 5 years, with a median of -$358.8 million in 2022.
• Across the five-year window, Enterprise Value jumped 83.44% in 2024 and tumbled 836.55% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$358.8 million in 2022, then sank by 76.75% to -$634.1 million in 2023, then soared by 83.44% to -$105.0 million in 2024, then tumbled by 836.55% to -$983.6 million in 2025, then soared by 76.39% to -$232.2 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$232.2 million in Q1 2026, -$983.6 million in Q4 2025, and -$1.1 billion in Q3 2025.